Center of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.
St John Fisher College, Wegnens School of Pharmacy, Rochester, NY, USA.
J Gen Intern Med. 2019 Aug;34(8):1554-1563. doi: 10.1007/s11606-019-05030-6. Epub 2019 Jun 3.
Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence. The Department of Veterans Health Affairs (VA) fills high volumes of inexpensive, over-the-counter sedating antihistamines and older antidepressants in addition to benzodiazepines and zolpidem. Yet little is known about the comparative safety of these agents with regard to suicidal behavior.
To assess the comparative effectiveness of the safety of medications routinely used to treat insomnia in VA.
Comparative effectiveness using propensity score-matched samples.
VA.
VA patients without any history of suicidal ideation or behavior 12 months prior to first exposure.
VA formularies and data were used to identify prescriptions for insomnia. Agents accounting for at least 1% of total insomnia fill volume were < 200 mg trazodone, hydroxyzine, diphenhydramine, zolpidem, lorazepam, diazepam, and temazepam. Exposure was defined as an incident monotherapy exposure preceded by 12 months without any insomnia medications. Subjects with insomnia polypharmacy or cross-overs in the 12 months following first exposure were excluded.
Suicide attempts within 12 months of first exposure.
Three hundred forty-eight thousand four hundred forty-nine subjects met criteria and three well-balanced cohorts by drug class matched to zolpidem were created. After adjusting for days' supply, mental health history, and pain and central nervous system medication history, hazard ratios (compared to zolpidem) were as follows: (< 200 mg) trazodone (HR = 1.61, 95% CI 1.07-2.43); sedating antihistamines (HR = 1.37, 95% CI 0.90-2.07); and benzodiazepines (HR = 1.31, 95% CI 0.85-2.08).
Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone (< 200 mg). No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia.
成人慢性失眠的药理学治疗指南认识到,尽管证据不足,但曲唑酮和其他超适应证药物仍被广泛处方。美国退伍军人事务部(VA)除了开具苯二氮䓬类药物和唑吡坦外,还大量开廉价的、非处方镇静性抗组胺药和较老的抗抑郁药。然而,关于这些药物在自杀行为方面的相对安全性,人们知之甚少。
评估 VA 常规用于治疗失眠的药物的相对安全性和有效性。
采用倾向评分匹配样本的比较有效性研究。
VA。
VA 患者在首次暴露前 12 个月内没有任何自杀意念或行为史。
VA 处方和数据用于确定失眠药物的处方。在总失眠药物使用量中占比至少为 1%的药物包括<200mg 曲唑酮、羟嗪、苯海拉明、唑吡坦、劳拉西泮、地西泮和替马西泮。暴露定义为在没有任何失眠药物治疗的情况下,首先使用单药治疗,持续 12 个月。在首次暴露后的 12 个月内有失眠药物联合用药或交叉用药的患者被排除在外。
首次暴露后 12 个月内的自杀企图。
34.849 万名患者符合标准,并根据药物类别与唑吡坦匹配创建了三个均衡的队列。在调整了用药天数、精神病史、疼痛和中枢神经系统药物史后,与唑吡坦相比,风险比(HR)如下:(<200mg)曲唑酮(HR=1.61,95%CI 1.07-2.43);镇静性抗组胺药(HR=1.37,95%CI 0.90-2.07);和苯二氮䓬类药物(HR=1.31,95%CI 0.85-2.08)。
与唑吡坦相比,曲唑酮(<200mg)的自杀企图风险增加了 61%。在苯二氮䓬类药物或镇静性抗组胺药与唑吡坦之间,自杀企图风险没有显著差异。这些发现为曲唑酮治疗失眠的相对有效性提供了首个证据。